These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30691964)

  • 1. Immunotherapy for LELC: Case Report and a Focused Review.
    Darrason M; Martin A; Soussan M; Chouahnia K; Pailler MC; Boudabous H; Brillet PY; Bousquet G; Zelek L; Duchemann B
    Clin Lung Cancer; 2019 May; 20(3):e393-e401. PubMed ID: 30691964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary pulmonary lymphoepithelioma-like carcinoma: fifty-two patients with long-term follow-up.
    Liang Y; Wang L; Zhu Y; Lin Y; Liu H; Rao H; Xu G; Rong T
    Cancer; 2012 Oct; 118(19):4748-58. PubMed ID: 22359203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
    Qiao M; Jiang T; Ren S; Zhou C
    Clin Lung Cancer; 2018 Jan; 19(1):1-11. PubMed ID: 28716463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.
    Lin Z; Fu S; Zhou Y; Zhang X; Chen C; He LN; Li H; Wang Y; Chen T; Zhang L; Hong S
    Lung Cancer; 2019 Nov; 137():100-107. PubMed ID: 31568886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1-targeted immunotherapy: recent clinical findings.
    Brahmer JR
    Clin Adv Hematol Oncol; 2012 Oct; 10(10):674-5. PubMed ID: 23187774
    [No Abstract]   [Full Text] [Related]  

  • 6. Thorough survey and analysis of pulmonary lymphoepithelioma-like carcinoma in Macau and multimodality treatment for advanced disease.
    Zhou N; Lin Y; Peng X; Wang Y; Wang Y
    Lung Cancer; 2019 Dec; 138():116-123. PubMed ID: 31683094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multimodality treatment and long-term follow-up of the primary pulmonary lymphoepithelioma-like carcinoma.
    Huang CJ; Feng AC; Fang YF; Ku WH; Chu NM; Yu CT; Liu CC; Lee MY; Hsu LH; Tsai SY; Shih CS; Wang CL
    Clin Lung Cancer; 2012 Sep; 13(5):359-62. PubMed ID: 22410385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical Analysis of Primary Pulmonary Lymphoepithelioma-like Carcinoma in 8 Patients].
    Zhao H; Chen J
    Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):168-175. PubMed ID: 32209185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies.
    Schulz C; Gandara D; Berardo CG; Rosenthal R; Foo J; Morel C; Ballinger M; Watkins C; Chu P
    Clin Lung Cancer; 2019 Nov; 20(6):451-460.e5. PubMed ID: 31375454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
    Santana-Davila R; Chow LQ
    Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
    [No Abstract]   [Full Text] [Related]  

  • 13. Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?
    Attili I; Passaro A; Pavan A; Conte P; De Marinis F; Bonanno L
    Crit Rev Oncol Hematol; 2017 Nov; 119():30-39. PubMed ID: 29065983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer.
    Pennell NA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S3-10. PubMed ID: 26477472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.
    Reck M
    Immunotherapy; 2018 Feb; 10(2):93-105. PubMed ID: 29145737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemo-immunotherapy: The Beginning of a New Era in Lung Cancer.
    Uprety D
    Clin Lung Cancer; 2019 Mar; 20(2):63-65. PubMed ID: 30545572
    [No Abstract]   [Full Text] [Related]  

  • 17. There and back again: An immunotherapy tale.
    Guo Y; Krupnick AS
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
    [No Abstract]   [Full Text] [Related]  

  • 18. Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction.
    Socinski MA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S1-2. PubMed ID: 26477469
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505).
    Gerber DE; Urbanic JJ; Langer C; Hu C; Chang IF; Lu B; Movsas B; Jeraj R; Curran WJ; Bradley JD
    Clin Lung Cancer; 2017 May; 18(3):333-339. PubMed ID: 27923550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
    Hoffner B; Leighl NB; Davies M
    Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.